NFKB1 and colorectal neoplasm: However, to our knowledge, this is the first report showing that both in vitro and in vivo, FDMC significantly inhibited colorectal tumour inflammation and angiogenesis in CCSCs and metastatic colon tumours by inhibiting NF-kB, VEGF, and MMP9 levels.